Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 240

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Protection against Plasmodium falciparum malaria by PfSPZ Vaccine

Open access
Epstein, Judith E., Paolino, Kristopher M., Richie, Thomas L., Sedegah, Martha, Singer, Alexandra, Ruben, Adam J., Chakravarty, Sumana, Stafford, April, Ruck, Richard C., Eappen, Abraham G., Li, Tao, Billingsley, Peter F., Manoj, Anita, Silva, Joana C., Moser, Kara, Nielsen, Robin, Tosh, Donna, Cicatelli, Susan, Ganeshan, Harini, Case, Jessica, Padilla, Debbie, Davidson, Silas, Garver, Lindsey, Saverino, Elizabeth, Murshedkar, Tooba, Gunasekera, Anusha, Twomey, Patrick S., Reyes, Sharina, Moon, James E., James, Eric R., KC, Natasha, Li, Minglin, Abot, Esteban, Belmonte, Arnel, Hauns, Kevin, Belmonte, Maria, Huang, Jun, Vasquez, Carlos, Remich, Shon, Carrington, Mary, Abebe, Yonas, Tillman, Amy, Hickey, Bradley, Regules, Jason, Villasante, Eileen, Sim, B. Kim Lee, Hoffman, Stephen L. · 2017 · JCI Insight

Abstract

BACKGROUND : A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously. The next step was to assess protective efficacy against heterologous Pf (different from Pf in the vaccine), after fewer doses, and at 24 weeks. METHODS : The trial assessed tolerability, safety, immunogenicity, and protective efficacy of direct venous inoculation (DVI) of 3 or 5 doses of PfSPZ Vaccine in non-immune subjects. RESULTS : Three weeks after final immunization, 5 doses of 2.7 × 10 5 PfSPZ protected 12 of 13 recipients (92.3% [95% CI: 48.0, 99.8]) against homologous CHMI and 4 of 5 (80.0% [10.4, 99.5]) against heterologous CHMI; 3 doses of 4.5 × 10 5 PfSPZ protected 13 of 15 (86.7% [35.9, 98.3]) against homologous CHMI. Twenty-four weeks after final immunization, the 5-dose regimen protected 7 of 10 (70.0% [17.3, 93.3]) against homologous and 1 of 10 (10.0% [–35.8, 45.6]) against heterologous CHMI; the 3-dose regimen protected 8 of 14 (57.1% [21.5, 76.6]) against homologous CHMI. All 22 controls developed Pf parasitemia. PfSPZ Vaccine was well tolerated, safe, and easy to administer. No antibody or T cell responses correlated with protection. CONCLUSIONS : We have demonstrated for the first time to our knowledge that PfSPZ Vaccine can protect against a 3-week heterologous CHMI in a limited group of malaria-naive adult subjects. A 3-dose regimen protected against both 3-week and 24-week homologous CHMI (87% and 57%, respectively) in this population. These results provide a foundation for developing an optimized immunization regimen for preventing malaria. TRIAL REGISTRATION : ClinicalTrials.gov NCT02215707. FUNDING : Support was provided through the US Army Medical Research and Development Command, Military Infectious Diseases Research Program, and the Naval Medical Research Center’s Advanced Medical Development Program.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.89154

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 240

Metadata

Authors
Epstein, J. E., Paolino, K. M., Richie, T. L., Sedegah, M., Singer, A., Ruben, A. J., Chakravarty, S., Stafford, A., Ruck, R. C., Eappen, A. G., Li, T., Billingsley, P. F., Manoj, A., Silva, J. C., Moser, K., Nielsen, R., Tosh, D., Cicatelli, S., Ganeshan, H., Case, J., Padilla, D., Davidson, S., Garver, L., Saverino, E., Murshedkar, T., Gunasekera, A., Twomey, P. S., Reyes, S., Moon, J. E., James, E. R., KC, N., Li, M., Abot, E., Belmonte, A., Hauns, K., Belmonte, M., Huang, J., Vasquez, C., Remich, S., Carrington, M., Abebe, Y., Tillman, A., Hickey, B., Regules, J., Villasante, E., Sim, B. K. L., & Hoffman, S. L.
Venue
JCI Insight
Published
2017-01-12
Volume
2
Issue
1
Pages
e89154-e89154
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2571810950
Cited by
240
References
2
FWCI
26.87
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. https://app.cochat.ai/papers/10.1172/jci.insight.89154
The paper
Epstein, J. E., Paolino, K. M., Richie, T. L., Sedegah, M., Singer, A., Ruben, A. J., Chakravarty, S., Stafford, A., Ruck, R. C., Eappen, A. G., Li, T., Billingsley, P. F., Manoj, A., Silva, J. C., Moser, K., Nielsen, R., Tosh, D., Cicatelli, S., Ganeshan, H., . . . Hoffman, S. L. (2017). Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight. https://doi.org/10.1172/jci.insight.89154

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.